(Q33914247)

30 July 2017

1 reference

title

Losartan: a review of its use, with special focus on elderly patients (English)

1 reference

30 July 2017

1 reference

K L Simpson

1

1 reference

30 July 2017

K J McClellan

series ordinal

2

1 reference

30 July 2017

publication date

1 March 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

16

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

227-250

1 reference

Additive Effects of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism on Blood Pressure and Renin Release in Sodium-Depleted Normotensives

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200016030-00006

Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200016030-00006

Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200016030-00006

Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200016030-00006

Recent progress in angiotensin II type 2 receptor research in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200016030-00006

Treatment of congestive heart failure in older persons

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200016030-00006

Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials

21 January 2018

1 reference

12 December 2020

The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension

1 reference

12 December 2020

Pharmacokinetics of intravenous and oral losartan in patients with heart failure

1 reference

12 December 2020

Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members

1 reference

12 December 2020

The management of chronic heart failure

1 reference

12 December 2020

Treatment guidelines in heart failure

1 reference

12 December 2020

Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Towards the better treatment of heart failure.

1 reference

12 December 2020

GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico

1 reference

12 December 2020

A risk-benefit assessment of losartan potassium in the treatment of hypertension

1 reference

12 December 2020

Guidelines for management of hypertension: report of the third working party of the British Hypertension Society

1 reference

12 December 2020

Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan

1 reference

12 December 2020

Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm

1 reference

12 December 2020

Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.

1 reference

12 December 2020

Drug selection for optimal treatment of hypertension in the elderly

1 reference

12 December 2020

Comparative pharmacology of the angiotensin II receptor antagonists

1 reference

12 December 2020

Effects of losartan on hypertension and left ventricular mass: a long-term study

1 reference

12 December 2020

Effect of enalapril on hemorheology in hypertensive patients with renal disease

1 reference

12 December 2020

Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications

1 reference

12 December 2020

Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension

1 reference

12 December 2020

Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise.

1 reference

12 December 2020

The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity

1 reference

12 December 2020

[3H]DUP 753, a highly potent and specific radioligand for the angiotensin II-1 receptor subtype

1 reference

12 December 2020

Angiotensin II receptor subtypes and their selective nonpeptide ligands

1 reference

12 December 2020

The pathophysiology of hypertension: the importance of angiotensin II in cardiovascular remodeling

1 reference

12 December 2020

Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension.

1 reference

12 December 2020

Enalapril (MK-421) and the white cell count and haematocrit

1 reference

12 December 2020

Effects of lisinopril and hydrochlorothiazide on platelet function and blood rheology in essential hypertension: a randomly allocated double-blind study

1 reference

12 December 2020

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

12 December 2020

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

1 reference

12 December 2020

Renal hemodynamics in essential hypertensives treated with losartan

1 reference

12 December 2020

Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension

1 reference

12 December 2020

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

1 reference

12 December 2020

Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators

1 reference

12 December 2020

Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist

1 reference

12 December 2020

Influence of cilazapril on blood rheology in healthy subjects. A pilot study

1 reference

12 December 2020

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

12 December 2020

The clinical significance of systolic hypertension

1 reference

12 December 2020

Dose-response relationships following oral administration of DuP 753 to normal humans

1 reference

12 December 2020

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

1 reference

12 December 2020

Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease

1 reference

12 December 2020

Endogenous angiotensin II and baroreceptor dysfunction: a comparative study of losartan and enalapril in man.

1 reference

12 December 2020

Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent

1 reference

12 December 2020

Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure

1 reference

12 December 2020

Current guidelines for the treatment of congestive heart failure

1 reference

12 December 2020

Consensus recommendations for the management of chronic heart failure

1 reference

12 December 2020

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

1 reference

12 December 2020

Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects

1 reference

12 December 2020

Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators

1 reference

12 December 2020

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension

1 reference

12 December 2020

Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent

1 reference

12 December 2020

Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension

1 reference

12 December 2020

Benefit of beta-blockers for heart failure: proven in 1999

1 reference

12 December 2020

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

1 reference

12 December 2020

Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man

1 reference

12 December 2020

Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers

1 reference

12 December 2020

Evaluating Health-related quality-of-life outcomes in patients with congestive heart failure. A review of recent randomised controlled trials

1 reference

12 December 2020

Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension

1 reference

12 December 2020

Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study

1 reference

12 December 2020

A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension

1 reference

12 December 2020

Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure

1 reference

12 December 2020

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

12 December 2020

The rationale for differing national recommendations for the treatment of hypertension.

1 reference

12 December 2020

Serum uric acid and cardiovascular events in successfully treated hypertensive patients

1 reference

12 December 2020

Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study.

1 reference

12 December 2020

Hypertension in the Elderly: An Update on Treatment Results and Recommendations - A Position Paper From the Council on Geriatric Cardiology

1 reference

12 December 2020

Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.

1 reference

12 December 2020

Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure

1 reference

12 December 2020

10.2165/00002512-200016030-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1042159447

0 references

1 reference